The province of Quebec is moving forward with changes to its recreational cannabis market as it attempts to combat supply challenges.

On Tuesday (February 26), the Société québécoise du cannabis (SQDC) signed supply agreements with licensed producers (LPs) Organigram Holdings (TSXV:OGI,OTCQX:OGRMF) and Zenabis Global (TSXV:ZENA,OTC Pink:ZBISF) to add product to its lineup of recreational marijuana.


Both producers will have to wait for the public process of the SQDC to determine the exact start date and final agreement in terms of quantity sold to the province.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Zenabis informed shareholders it expects to supply product starting the second quarter of 2019.

This agreement for both marijuana firms represents an increase in the presence of their products across Canada.

Thanks to the deal, Zenabis product will be available in nine provinces, while Quebec was the last province missing in Organigram’s portfolio.

“This relationship represents an additional significant relationship with a provincial counterparty,” Andrew Grieve, CEO of Zenabis, said in a press release.

Organigram indicated it plans to supply Quebec with “mainstream, value and premium flower, along with an assortment of pre-rolls and oils.”

Greg Engel, Organigram’s CEO, said his company would build on the relationship with provincial bodies as “we look ahead to the legalization of cannabis edibles.”

Shares of Zenabis closed on Tuesday at a price of C$3.68, while Organigram finished the day priced at C$8.53.

On Wednesday, share prices for both producers declined with Organigram decreasing 2.23 percent for a price of C$8.34 and Zenabis dropping 0.27 percent for a finishing price of C$3.67.

Quebec adjusts restrictions on marijuana shops

Quebec implemented for its government-run stores to be closed three days a week in order to maintain its supply of recreational product.

On Tuesday, CBC reported the province had reduced this restriction to two days.

“We know that we are now capable of opening all the stores another day in the week because we know that our supply logistics can sustain the whole network,” SQDC spokesperson Fabrice Giguère said.

At the end of January, the SQDC reported it had sold 5.7 tonnes of legal cannabis, resulting in C$40 million during its first three months of sales.

“To diversify its pool of suppliers, the SQDC issued a call for tenders for products in December and is studying the bids received,” the provincial agency informed consumers. “That said, no significant increase in supply will occur before late spring 2019.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less